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Metformin has been a first-line treatment for type II
diabetes mellitus for decades and is the most widely
prescribed antidiabetic drug. Retrospective studies
have found that metformin treatment is associated
with both reduced cancer diagnoses and cancer-related
deaths. Despite the prevalence of metformin use in
the clinic, its molecular mechanism of action remains
controversial. In a recent issue of Cancer & Metabolism,
Andrzejewski et al. present evidence that metformin
acts directly on mitochondria to inhibit complex I and
limits the ability of cancer cells to cope with energetic
stress. Here, we discuss evidence that supports the role
of metformin as a cancer therapeutic.
See research article:
http://www.cancerandmetabolism.com/content/2/1/12.mitochondrial respiration and decreases proton-driven
synthesis of ATP, causing cellular energetic stress and ele-The biguanide metformin is an antihyperglycemic agent
used to treat type II diabetes. Metformin decreases blood
glucose levels by suppressing liver gluconeogenesis and
stimulating glucose uptake in skeletal muscle and adi-
pose tissues. Metformin is prescribed to over 120 million
people, providing a wealth of epidemiological data. Retro-
spective studies have found that metformin treatment is
associated with diminished tumorigenesis, with a recent
meta-analysis of these studies reporting a 31% reduction
in cancer incidence and a 34% reduction in cancer-specific
mortality across many tumor types [1]. While these find-
ings are provocative, it remains controversial whether the
effects of metformin on improving cancer outcomes are
a result of altered whole body metabolism or if metfor-
min can act in a cell autonomous manner. Indeed, the* Correspondence: mvh@mit.edu
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unless otherwise stated.anticancer action of metformin can be divided into two
categories: ‘indirect effects’ resulting from systemic
changes in metabolism, such as reduced concentrations
of blood glucose and insulin, and ‘direct effects’ on
tumor cells (Figure 1). Importantly, both could act syn-
ergistically or have differential importance depending
on the cancer context. The molecular mechanisms by
which metformin can impact tumor biology are an area
of active research and clinical trials are ongoing to de-
fine the role of metformin in cancer treatment.Metformin action on cells and tissues
Although the molecular underpinnings of metformin ac-
tion remain an area of active investigation, the best de-
scribed mechanism is inhibition of complex I, the first
component of the mitochondrial electron transport chain
(Figure 2). Complex I inhibition by metformin interrupts
vation of the AMP:ATP ratio. These changes result in
allosteric activation of 5’-AMP-activated protein kinase
(AMPK), a primary metabolic sensor. Hepatic AMPK acti-
vation can inhibit gluconeogenesis and activates glycolysis
[2]. AMPK activation in the muscle can also increase glu-
cose consumption, and is another potential site of metfor-
min action [3]. Both of these consequences of metformin
can lower blood glucose and contribute to therapeutic
benefit in in type II diabetes.
Though AMPK was once considered the primary
executor of metformin antidiabetic action, genetic loss-
of-function studies in mice have indicated that hepatic
expression of AMPK and its upstream activating kinase
LKB1 may not be absolutely required for suppression of
gluconeogenesis by metformin [4]. An AMPK-independent
mechanism has been proposed, by which metformin antag-
onizes glucagon-dependent cyclic AMP (cAMP) signaling
[5]. Glucagon activates adenylyl cyclase to produce cAMP
and stimulate cAMP-dependent protein kinase (PKA)l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1. Indirect and direct effects of metformin on tumors. Metformin can suppress tumor progression by modulating metabolic whole
body physiology or by acting directly on cancer cells. Metformin diminishes hepatic glucose output leading to lower systemic glucose and
insulin levels, which could impair malignant growth indirectly without requiring accumulation of metformin in the tumor. Alternatively,
metformin can act on cancer cells directly, inhibiting cancer progression by suppressing mTOR signaling, mitochondrial glucose oxidation, and/or
reducing stability of HIF under hypoxic conditions.
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sphate levels, thereby favoring gluconeogenesis in the liver
and increasing blood glucose levels. Metformin opposes
glucagon action because inhibition of the mitochondrial
electron transport chain elevates cytosolic AMP:ATP
ratios, which in turn abrogates cAMP production [5].
Therefore, inhibition of PKA signaling by metformin
may be another mechanism for inhibition of hepatic
gluconeogenesis and reduced hyperglycemia in patients
treated with the drug.
In addition to targeting complex I, metformin has re-
cently been shown to inhibit mitochondrial glycerol-
phosphate dehydrogenase (mGPD; Figure 2) [6]. mGPD
transports cytosolic reducing equivalents from NADH into
the mitochondria via the glycerol-phosphate shuttle. Inter-
estingly, inhibition of mGPD and complex I both com-
promise the ability of mitochondria to oxidize cytosolic
NADH and decrease the entry of these reducing equiva-
lents into the electron transport chain. Therefore, both
complex I and mGPD inhibition are expected to have simi-
lar downstream consequences on cellular bioenergetics.
Regardless of how metformin disrupts mitochondrial
respiration, the resulting energy stress, changes in cofactor
balance, and reliance on alternative metabolic pathways to
obtain ATP could have several effects that contribute to
the therapeutic benefits of this drug. AMPK activation,
PKA inhibition, and redox stress may act separately or in
concert to repress hepatic gluconeogenesis and stimulate
insulin sensitivity. There are many ways in which metfor-
min might act across tissues to alter metabolic physiology,and these complexities make it challenging to understand
how metformin improves outcomes in cancer patients.
Role of metformin in cancer therapy
The association between metformin and decreased can-
cer risk may be a result of the antidiabetic effects of the
drug. Increased glucose consumption is a hallmark of
many cancer cells, and increased blood glucose and insu-
lin levels seen in type II diabetes are associated with worse
cancer prognosis [7]. Metformin improves glycemic con-
trol and lowers insulin levels, which can influence other
hormones and cytokines, including insulin-like growth
factor 1 (IGF-1), a known mitogen that has been shown to
promote carcinogenesis. Most of the patients in existing
retrospective metformin studies were diabetic, so on-
going efforts to define the benefit of metformin in non-
diabetic cancer patients will provide important insight
into the role indirect metformin effects play in im-
proved cancer outcomes.
Metformin affects systemic metabolism, but can also
influence cell autonomous energetics. Metformin treat-
ment leads to energy stress and AMPK activation in can-
cer cells, which can impair proliferation by suppressing
anabolic processes and growth signaling through mam-
malian target of rapamycin (mTOR). Increased mTOR
activation has been implicated in a wide variety of differ-
ent cancers, and AMPK-mediated attenuation of ana-
bolic metabolism and/or mTOR signaling by metformin
may contribute to the antitumor effects of metformin in
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Figure 2. Cellular consequences of metformin action at the mitochondria. Metformin enters the cell by organic cation transporter 1 (OCT1),
where it then accumulates in the mitochondria. There, metformin inhibits complex I of the electron transport chain and mGDP, resulting in
decreased NADH oxidation. Decreased electron chain activity suppresses tricarboxylic acid (TCA) cycle flux and decreases mitochondrial ATP
synthesis. These actions result in increased AMPK signaling, decreased cAMP/PKA signaling, decreased gluconeogenesis and increased glycolysis.
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particularly sensitive to biguanides [8]. This suggests that
induction of energy stress may account for some of the
ability of metformin to limit cancer progression.
The findings of Andrzejewski et al. [9] support the ob-
servation that metformin-mediated energy imbalances
can cause toxicity in cells. They demonstrate that met-
formin acts directly on mitochondrial complex I in can-
cer cells, limiting respiration and blocking glucose entry
into the tricarboxylic acid cycle. It has long been known
that malignant cells avidly consume glucose and prefer-
entially metabolize glucose to lactate. However, studies
of tumor metabolism in vivo have suggested that some
tumor cells also oxidize glucose in the mitochondria[10]. Since metformin prevents mitochondrial glucose
metabolism, metformin might be particularly effective in
tumors that rely on glucose oxidation via the tricarb-
oxylic acid cycle.
Decreased vascularization of tumors affects the avail-
ability of both glucose and oxygen and may influence
how glucose is used by cancer cells in vivo. Stabilization
of hypoxia-inducible factors (HIFs) is a critical part of
the metabolic adaptation to low-oxygen and activation
of HIFs is reported in many cancers [11]. Metformin has
recently been shown to reduce hypoxia-induced HIF1α
stabilization and diminish expression of HIF target genes
in tumors [12], suggesting that metformin may serve a
therapeutic role in cancers that are dependent on HIF
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understanding of the signaling and metabolic effects of
metformin on cancer cells will help define other tumor
contexts likely to be sensitive to metformin.
Despite increasing evidence that metformin can have
profound effects on cancer cells, it is not well understood
if the drug accumulates to sufficient levels to cause these
direct effects in patient tumors. The liver is a clear site of
drug action, as it is exposed to high levels of oral metfor-
min and expresses the metformin transporter OCT1, fa-
cilitating uptake and allowing for drug accumulation in
this tissue. At metformin doses prescribed to diabetic pa-
tients, the circulating levels in plasma and peripheral tis-
sues are orders of magnitude below the concentrations
used in vitro to elicit a biological effect in cancer cells.
How the concentrations used in vitro translate to the ef-
fects on tumor tissues remains controversial, but some
studies have shown that metformin induces cancer au-
tonomous metabolic changes in vivo. Metformin has been
shown to activate AMPK in intestinal tumors, even in the
absence of changes in organismal blood glucose or insulin
levels [13]. In another study, tumors engineered to express
a surrogate for complex I that is refractory to metformin
are resistant to the drug in vivo [12]. These data argue that
the direct effect of metformin on mitochondrial electron
transport can be relevant for tumor growth in a cell au-
tonomous manner. A better understanding of the pharma-
cokinetic properties and the molecular mechanisms of
metformin will better define how best to use this antidia-
betic drug in cancer therapy.References
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